Harbert Management Corporation and Claret Capital Partners Announce Close of Transaction
29.10.2020 14:39:00 EET | Business Wire | Press release
Harbert Management Corporation (“HMC”) and Claret Capital Partners Limited (“Claret”), a company formed by David Bateman and Johan Kampe, are pleased to announce the closing of a transaction by which Claret has assumed full ownership and control of the general partners of Harbert European Growth Capital (“HEGC”) investment funds, including Harbert European Growth Capital Fund I, L.P. (“HEGCF I”), Harbert European Growth Capital Fund II, SCSp (“HEGCF II”) and the newly launched Harbert / Claret European Growth Capital Fund III, SCSp (“HEGCF III”). HMC and its affiliates will remain investors in HEGCF I and HEGCF II, and HMC’s interests continue to be aligned with investors in HEGCF I and HEGCF II.
In connection with the transaction, Claret is hiring the entire HEGC investment team, assuming the lease for their current office space in London and acquiring related assets from HMC. Johan Kampe, Managing Partner of Claret, said “Over the past seven years, we have built a fantastic team of investment professionals who have proven to be outstanding stewards of the capital invested through HEGCF I and HEGCF II. This investment team will remain the same, and their activities are expected to continue seamlessly as we commence investing HEGCF III.”
As a result of the transaction, Claret now manages, or has arranged for the third party management of, the HEGC funds commencing October 26, 2020. While HMC no longer serves as the investment manager for HEGCF I and HEGCF II, HMC will continue to provide operational support and assistance to Claret consistent with past practices pursuant to a services agreement. David Bateman, Managing Partner of Claret, said “We are grateful for our seven year partnership with HMC, during which time we learned a great deal about managing investment funds. This experience has prepared us well to take the next step in the evolution of the HEGC strategy and consolidate investment and operational functions within Claret, of course working with our chosen third party managers, and with the continuing support of HMC. We are very excited to be taking this step.”
HMC and the principals of Claret formed HEGCF I in partnership together in 2013, and over the past seven years have built one of the preeminent providers of venture and growth debt to SMEs in Europe, with over €400 million invested in over 120 European SMEs and recognition as Investor All Stars – 2019 Specialty Debt Provider of the Year. Raymond Harbert, Chief Executive Officer of HMC, said “As we look back over the last seven years, we are proud of what we have accomplished together with the Harbert European Growth Capital strategy, and we remain very pleased with our investments in the HEGC funds. However, as I look forward into the future, it is clear to me that the time is right for David and Johan to take this strategy into the future from Europe, independent of HMC, but with HMC’s full support.”
For More Information
Visit:
www.claret-capital.com
###
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005642/en/
Contact information
Lyall Davenport
+44(0) 7481 492996
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mexico Becomes the First Market Worldwide to Receive Approval for Galderma’s Restylane ® Shaype™ for Both Chin and Its First Jawline Indication13.11.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that Restylane Shaype has been approved for temporary augmentation in the chin area and improvement of jawline definition in Mexico.1 This is the product’s first approval globally for the jawline, and further expands its availability for chin augmentation, where it is already approved across various markets globally including Europe, Brazil, Canada and Thailand. Restylane Shaype has been purposefully developed as a firmer gel to deliver a unique bone-mimicking effect and enable natural-looking structural enhancement without surgery.3-6 The lower face plays a pivotal role in overall facial balance, influencing proportions and profile,4 with recent market research conducted by Galderma finding that the chin is the third most treated area in existing HA injectable users.7 In the chin, genetic factors and age-related changes can lead to reduced definition and poor projection.4,8 In the jawline, factors such as
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 07:02:00 EET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*13.11.2026 00:07:00 EET | Press release
The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience brings Percy Jackson’s adventures off the screen and into the ‘World’s Most Famous Building,’ where guests ca
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
